PMID- 30970006
OWN - NLM
STAT- MEDLINE
DCOM- 20191230
LR  - 20200309
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 4
DP  - 2019
TI  - A lipid-free and insulin-supplemented medium supports De Novo fatty acid 
      synthesis gene activation in melanoma cells.
PG  - e0215022
LID - 10.1371/journal.pone.0215022 [doi]
LID - e0215022
AB  - While investigating the role played by de novo lipid (DNL) biosynthesis in cancer 
      cells, we sought a medium condition that would support cell proliferation without 
      providing any serum lipids. Here we report that a defined serum free cell culture 
      medium condition containing insulin, transferrin and selenium (ITS) supports 
      controlled study of transcriptional regulation of de novo fatty acid (DNFA) 
      production and de novo cholesterol synthesis (DNCS) in melanoma cell lines. This 
      lipid-free ITS medium is able to support continuous proliferation of several 
      melanoma cell lines that utilize DNL to support their lipid requirements. We show 
      that the ITS medium stimulates gene transcription in support of both DNFA and 
      DNCS, specifically mediated by SREBP1/2 in melanoma cells. We further found that 
      the ITS medium promoted SREBP1 nuclear localization and occupancy on DNFA gene 
      promoters. Our data show clear utility of this serum and lipid-free medium for 
      melanoma cancer cell culture and lipid-related areas of investigation.
FAU - Wu, Su
AU  - Wu S
AUID- ORCID: 0000-0002-7317-3389
AD  - Massachusetts General Hospital Center for Cancer Research, Charlestown, 
      Massachusetts, United States of America.
AD  - Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United 
      States of America.
FAU - Naar, Anders M
AU  - Naar AM
AD  - Massachusetts General Hospital Center for Cancer Research, Charlestown, 
      Massachusetts, United States of America.
AD  - Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United 
      States of America.
LA  - eng
GR  - R01 HL116391/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190410
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Culture Media)
RN  - 0 (Fatty Acids)
RN  - 0 (Insulin)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (SREBF1 protein, human)
RN  - 0 (SREBF2 protein, human)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - 0 (Sterol Regulatory Element Binding Protein 2)
RN  - 0 (Transferrin)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - H6241UJ22B (Selenium)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Nucleus/metabolism
MH  - Cell Proliferation/drug effects
MH  - Cholesterol/biosynthesis
MH  - Culture Media/chemistry
MH  - Fatty Acids/*biosynthesis
MH  - Humans
MH  - Insulin/*pharmacology
MH  - Melanoma/metabolism/pathology
MH  - RNA Interference
MH  - RNA, Small Interfering/metabolism
MH  - Selenium/pharmacology
MH  - Sterol Regulatory Element Binding Protein 1/antagonists & 
      inhibitors/*genetics/metabolism
MH  - Sterol Regulatory Element Binding Protein 2/antagonists & 
      inhibitors/*genetics/metabolism
MH  - Transcriptional Activation/*drug effects
MH  - Transferrin/pharmacology
PMC - PMC6457551
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/04/11 06:00
MHDA- 2019/12/31 06:00
PMCR- 2019/04/10
CRDT- 2019/04/11 06:00
PHST- 2018/11/20 00:00 [received]
PHST- 2019/03/25 00:00 [accepted]
PHST- 2019/04/11 06:00 [entrez]
PHST- 2019/04/11 06:00 [pubmed]
PHST- 2019/12/31 06:00 [medline]
PHST- 2019/04/10 00:00 [pmc-release]
AID - PONE-D-18-33387 [pii]
AID - 10.1371/journal.pone.0215022 [doi]
PST - epublish
SO  - PLoS One. 2019 Apr 10;14(4):e0215022. doi: 10.1371/journal.pone.0215022. 
      eCollection 2019.